Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
07:00am, Thursday, 08'th Jan 2026
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNews
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
07:00am, Wednesday, 07'th Jan 2026
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a
Viking Therapeutics (NASDAQ:VKTX) Director Matthew Foehr Sells 16,000 Shares
05:20am, Tuesday, 06'th Jan 2026
Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) Director Matthew Foehr sold 16,000 shares of the business's stock in a transaction on Friday, January 2nd. The stock was sold at an average p
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Monday, 05'th Jan 2026
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.12, denoting a -9.32% move from the preceding trading day.
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:03pm, Monday, 05'th Jan 2026
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and
Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over
10:00am, Saturday, 03'rd Jan 2026
Viking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase. VKTX's dual-track pipeline (injectable and oral) and robust $700M liquidity position it wel
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
10:07am, Friday, 02'nd Jan 2026
Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
Viking Therapeutics: A Wide-Open Oral GLP-1 Market
02:13am, Thursday, 01'st Jan 2026
Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 week
2 Beaten-Down Stocks That Could Bounce Back in 2026
08:55am, Wednesday, 31'st Dec 2025
Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges.
Viking Therapeutics (NASDAQ:VKTX) and Revelation Biosciences (NASDAQ:REVB) Head to Head Contrast
01:49am, Wednesday, 31'st Dec 2025
Revelation Biosciences (NASDAQ: REVB - Get Free Report) and Viking Therapeutics (NASDAQ: VKTX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:45pm, Tuesday, 30'th Dec 2025
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $35.32, marking a -3.13% move from the previous day.
Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain
09:40am, Sunday, 28'th Dec 2025
VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The managem
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
06:46pm, Tuesday, 23'rd Dec 2025
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $36.41, marking a +2.85% move from the previous day.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
10:31am, Tuesday, 23'rd Dec 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Rating of “Moderate Buy” from Brokerages
01:28am, Tuesday, 23'rd Dec 2025
Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the company, MarketBeat Ratings
